Effect of É-3 polyunsaturated fatty acids plus low dose of aspirin daily supplementation as adjunctive to full-mouth ultrasonic debridement for the treatment of chronic periodontitis in type 2 diabetic patients. Superiority randomized clinical trial
Diabetes mellitus (DM) has become a global epidemic. Its complications can have a significant impact on quality of life, longevity, and costs in public health. The World Health Organization (WHO) estimates that by 2030, 439 million people will suffer from diabetes, around 10% of the world adult population (WHO, 2011). In Brazil, the Brazilian Society of Diabetes estimates that 12 million people have the disease, which represents a prevalence of approximately 7%. Periodontal Diseases are considered the sixth complication of DM. This close relationship between both diseases is characterized by mutual influence. Thus, an appropriate control of periodontal disease may facilitate the DM control, improving quality of life on diabetes patients. Besides that, the presence of DM might impair prognosis of diverse dental treatments due to its inflammatory nature, negative influence on wound healing, on bone biology, and the establishment of infections. Recently, daily supplementation with omega-3 polyunsaturated fatty acids and aspirin has been proposed as adjunct therapy to the treatment of chronic periodontitis, showing good clinical and metabolic results in normoglycemic patients. Therefore, the aim of this study is to investigate the effectiveness of daily supplementation with omega-3 polyunsaturated fatty acids and aspirin as adjunct therapy to full-mouth ultrasonic periodontal debridement for the treatment of chronic periodontitis in type 2 diabetic patients through a randomized superiority clinical trial.
News published in Agência FAPESP Newsletter about the scholarship: